Solventum Corporation (SOLV) earnings on August 5, 2026
More Solventum Corporation earnings
Prior outlook: Optimistic Outcome: Partial
Solventum fell 4.74% despite analysts upgrading the stock and raising price targets. The stock had risen 5.88% during the day before closing lower.
SOLV price around the earnings
82.96
Change: -5.0%
2026-08-06, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Partial
- Thesis published
- Results released
Strong positive trend strength and strong recent earnings beat history, but analyst consensus implies slight downside.
Context analyzed before publication
- Trend
- Consistent positive trend strength and relative strength, strengthening into earnings, indicating high expectations.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 2.2
- Analysts covering the stock
- 13
- Average price target
- 84.69
- Lowest price target
- 60
- Highest price target
- 100
- Upside to price target
- -2.2%
- Quarterly earnings growth
- -90.5%
- Revenue growth
- -3%
- Forward EPS
- 7.09
- Trailing EPS
- 8.17
- Analyst moves in the last 60 days
- 2
- Strong buy: 1
- Buy: 7
- Hold: 5
- Sell: 1
- Strong sell: 1
- Strong buy
- 1
- Buy
- 7
- Hold
- 5
- Sell
- 1
- Strong sell
- 1
- July 28, 2026 · UBS: Upgrades rating (Neutral → Buy)
- July 9, 2026 · BMO Capital: Initiates coverage (Market Perform)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 95.7%
News
Sources (2)
- UBS Upgrades Solventum to Buy, Announces $95 Price Target (opens in a new tab) — Benzinga
- BMO Capital Initiates Coverage On Solventum with Market Perform Rating, Announces Price Target of $81 (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 87.93
- Average true range (ATR)
- 2.6%
- Distance to 52-week high
- -2.2%
- 14-day change (14d)
- +11.7%
- 30-day change (33d)
- +12.4%
- 30-day relative strength
- +8.9%
- SPY change (33d)
- +3.5%
- Nearest support
- 87.06
- Distance to nearest support
- 1%
- Nearest resistance
- 88.2
- Distance to nearest resistance
- 0.3%
- Volume accumulation ratio (14d / 46d)
- 0.95
- Mid: 87.06 (1% away, 0.38 ATR, 8 touches)
- Mid: 86.14 (2% away, 0.78 ATR, 14 touches)
- Minor: 85.46 (2.8% away, 1.07 ATR, 8 touches)
- Mid: 88.2 (0.3% away, 0.12 ATR, 10 touches)
Trends
Evidence
- Average earnings surprise
- +8.8%
- May 5, 2026: actual EPS 1.48 vs estimate 1.35 (surprise +9.3%)
- February 26, 2026: actual EPS 1.57 vs estimate 1.5 (surprise +5.0%)
- November 6, 2025: actual EPS 1.5 vs estimate 1.43 (surprise +4.7%)
- August 7, 2025: actual EPS 1.69 vs estimate 1.45 (surprise +16.3%)
Expected move
- Implied move
- +2.2%
- Source
- Options chain
Reactions over its last 9 earnings
- Median move
- 3.5%
- 75th percentile move
- 4.4%
- 90th percentile move
- 6.1%
- Up / down moves
- 5 / 4
- Average up move
- +4.3%
- Average down move
- -3.6%
Monitoring and close
What Solventum Corporation reported
- Status
- Finished
| Actual EPS | 2.55 |
|---|---|
| EPS estimate | 1.91 |
| EPS surprise | +33.5% |
| Revenue | $2,209 million |
| Revenue estimate | $2,156 million |
| Revenue surprise | +2.5% |
Solventum beat Q2 expectations with adjusted EPS of $2.55 and sales of $2.209 billion. The company plans to separate its health information systems operations.
Sources (4)
- Solventum Plans To Separate Its Health Information Systems Operations As Part Of Its Portfolio Optimization Strategy (opens in a new tab) — Benzinga
- Solventum beat expectations in Q2: adjusted EPS of $2.55 and sales of $2.209 billion, both above estimates. — Benzinga
- Solventum Q2 Adj. EPS $2.55 Beats $1.91 Estimate, Sales $2.209B Beat $2.156B Estimate (opens in a new tab) — Benzinga
- Solventum Raises FY2026 Adj EPS Guidance from $6.60 to $7.10-$7.20 vs $6.55 Est (opens in a new tab) — Benzinga
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating +1.3% pre-market, a move below the stock's usual reaction (about 4%). The figures confirm the optimistic scenario. In the 1,401 similar cases in our market history, the close held that direction 72% of the time.
How the stock reacted
- Outcome
- Partial
- Consolidated
- -4.7%
- Max favorable move (MFE)
- 5.9%
- Max adverse move (MAE)
- 5.8%